QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-cardiff-oncology-lowers-price-target-to-10

HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and lowers the price target...

 why-is-cardiff-oncology-stock-trading-lower-after-colorectal-cancer-data

Onvansertib combined with standard care showed up to 49% confirmed ORR in RAS-mutated colorectal cancer, with early signs of PF...

 cardiff-oncology-shares-slide-over-26-in-premarket-trading-after-mixed-q2

Cardiff Oncology Inc. (NASDAQ: CRDF) plummeted 22.96% in its stock value on Tuesday, following a disappointing second quarter e...

 cardiff-oncology-reports-49-orr-with-onvansertib-in-phase-2-mcrc-trial

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-t...

 cardiff-oncology-q2-eps-021-misses-020-estimate-sales-12100k-beat-9286k-estimate

Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(...

 cardiff-oncology-announces-data-from-ongoing-randomized-phase-2-first-line-ras-mutated-mcrc-clinical-trial

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-t...

 ladenburg-thalmann-initiates-coverage-on-cardiff-oncology-with-buy-rating-announces-price-target-of-19

Ladenburg Thalmann analyst Kevin DeGeeter initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Buy rating and announc...

 jefferies-initiates-coverage-on-cardiff-oncology-with-hold-rating-announces-price-target-of-35

Jefferies analyst Maury Raycroft initiates coverage on Cardiff Oncology (NASDAQ:CRDF) with a Hold rating and announces Price...

 cardiff-oncology-presents-data-from-investigator-initiated-phase-1b-clinical-trial-evaluating-onvansertib-in-combination-with-paclitaxel-in-patients-with-mtnbc-at-2025-asco-annual-meeting

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonst...

 hc-wainwright--co-maintains-buy-on-cardiff-oncology-raises-price-target-to-18

HC Wainwright & Co. analyst Robert Burns maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION